213 related articles for article (PubMed ID: 9932945)
1. A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms.
Collado-Seidel V; Kazenwadel J; Wetter TC; Kohnen R; Winkelmann J; Selzer R; Oertel WH; Trenkwalder C
Neurology; 1999 Jan; 52(2):285-90. PubMed ID: 9932945
[TBL] [Abstract][Full Text] [Related]
2. Acute double-blind, placebo-controlled sleep laboratory and clinical follow-up studies with a combination treatment of rr-L-dopa and sr-L-dopa in restless legs syndrome.
Saletu M; Anderer P; Högl B; Saletu-Zyhlarz G; Kunz A; Poewe W; Saletu B
J Neural Transm (Vienna); 2003 Jun; 110(6):611-26. PubMed ID: 12768357
[TBL] [Abstract][Full Text] [Related]
3. Rapid onset of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial.
Benes H; Kurella B; Kummer J; Kazenwadel J; Selzer R; Kohnen R
Sleep; 1999 Dec; 22(8):1073-81. PubMed ID: 10617168
[TBL] [Abstract][Full Text] [Related]
4. Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome.
Polo O; Ylä-Sahra R; Hirvonen K; Karvinen J; Vahteristo M; Ellmén J
Clin Neuropharmacol; 2007; 30(6):335-44. PubMed ID: 18090458
[TBL] [Abstract][Full Text] [Related]
5. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial.
Trenkwalder C; Stiasny K; Pollmächer T; Wetter T; Schwarz J; Kohnen R; Kazenwadel J; Krüger HP; Ramm S; Künzel M
Sleep; 1995 Oct; 18(8):681-8. PubMed ID: 8560135
[TBL] [Abstract][Full Text] [Related]
6. One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome?
Trenkwalder C; Collado Seidel V; Kazenwadel J; Wetter TC; Oertel W; Selzer R; Kohnen R
Mov Disord; 2003 Oct; 18(10):1184-9. PubMed ID: 14534925
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of idiopathic and uremic restless legs syndrome with L-dopa--a double-blind cross-over study].
Wetter TC; Trenkwalder C; Stiasny K; Pollmächer T; Kazenwadel J; Kohnen R; Künzel M; Oertel WH
Wien Med Wochenschr; 1995; 145(17-18):525-7. PubMed ID: 8588396
[TBL] [Abstract][Full Text] [Related]
8. Ropinirole as a treatment of restless legs syndrome in patients on chronic hemodialysis: an open randomized crossover trial versus levodopa sustained release.
Pellecchia MT; Vitale C; Sabatini M; Longo K; Amboni M; Bonavita V; Barone P
Clin Neuropharmacol; 2004; 27(4):178-81. PubMed ID: 15319704
[TBL] [Abstract][Full Text] [Related]
9. Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study.
Brodeur C; Montplaisir J; Godbout R; Marinier R
Neurology; 1988 Dec; 38(12):1845-8. PubMed ID: 3057399
[TBL] [Abstract][Full Text] [Related]
10. Levodopa for idiopathic restless legs syndrome: evidence-based review.
Conti CF; de Oliveira MM; Andriolo RB; Saconato H; Atallah AN; Valbuza JS; Coin de Carvalho LB; do Prado GF
Mov Disord; 2007 Oct; 22(13):1943-51. PubMed ID: 17659645
[TBL] [Abstract][Full Text] [Related]
11. Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa.
Staedt J; Wassmuth F; Ziemann U; Hajak G; Rüther E; Stoppe G
J Neural Transm (Vienna); 1997; 104(4-5):461-8. PubMed ID: 9295178
[TBL] [Abstract][Full Text] [Related]
12. Restless legs syndrome and its treatment by dopamine agonists.
Stiasny K; Wetter TC; Trenkwalder C; Oertel WH
Parkinsonism Relat Disord; 2000 Nov; 7(1):21-25. PubMed ID: 11008192
[TBL] [Abstract][Full Text] [Related]
13. Pramipexole versus dual release levodopa in restless legs syndrome: a double blind, randomised, cross-over trial.
Bassetti CL; Bornatico F; Fuhr P; Schwander J; Kallweit U; Mathis J;
Swiss Med Wkly; 2011; 141():w13274. PubMed ID: 22101745
[TBL] [Abstract][Full Text] [Related]
14. L-Dopa improves Restless Legs Syndrome and periodic limb movements in sleep but not Attention-Deficit-Hyperactivity Disorder in a double-blind trial in children.
England SJ; Picchietti DL; Couvadelli BV; Fisher BC; Siddiqui F; Wagner ML; Hening WA; Lewin D; Winnie G; Cohen B; Walters AS
Sleep Med; 2011 May; 12(5):471-7. PubMed ID: 21463967
[TBL] [Abstract][Full Text] [Related]
15. A dose-ranging study of pramipexole for the symptomatic treatment of restless legs syndrome: polysomnographic evaluation of periodic leg movements and sleep disturbance.
Jama L; Hirvonen K; Partinen M; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
Sleep Med; 2009 Jun; 10(6):630-6. PubMed ID: 19171500
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR).
Oertel WH; Benes H; Bodenschatz R; Peglau I; Warmuth R; Happe S; Geisler P; Cassel W; Leroux M; Kohnen R; Stiasny-Kolster K
Neurology; 2006 Sep; 67(6):1040-6. PubMed ID: 16931508
[TBL] [Abstract][Full Text] [Related]
17. Low-dose pramipexole in the management of restless legs syndrome. An open label trial.
Stiasny-Kolster K; Oertel WH
Neuropsychobiology; 2004; 50(1):65-70. PubMed ID: 15179023
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of pergolide in treatment of restless legs syndrome: the PEARLS Study.
Trenkwalder C; Hundemer HP; Lledo A; Swieca J; Polo O; Wetter TC; Ferini-Strambi L; de Groen H; Quail D; Brandenburg U;
Neurology; 2004 Apr; 62(8):1391-7. PubMed ID: 15111679
[TBL] [Abstract][Full Text] [Related]
19. L-DOPA/carbidopa for nocturnal movement disorders in uremia.
Walker SL; Fine A; Kryger MH
Sleep; 1996 Apr; 19(3):214-8. PubMed ID: 8723378
[TBL] [Abstract][Full Text] [Related]
20. Treatment of idiopathic restless legs syndrome (RLS) with the D2-agonist cabergoline--an open clinical trial.
Stiasny K; Röbbecke J; Schüler P; Oertel WH
Sleep; 2000 May; 23(3):349-54. PubMed ID: 10811379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
